# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer.Elevated levels of s...
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one con...
23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.14) per share. The company reported quarterly sales of $40.000 mi...